GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Marksans Pharma Ltd (NSE:MARKSANS) » Definitions » Effective Interest Rate on Debt %

Marksans Pharma (NSE:MARKSANS) Effective Interest Rate on Debt % : 4.27% (As of Mar. 2025)


View and export this data going back to 2002. Start your Free Trial

What is Marksans Pharma Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Marksans Pharma's annualized positive value of Interest Expense for the quarter that ended in Mar. 2025 was ₹137 Mil. Marksans Pharma's average total debt for the quarter that ended in Mar. 2025 was ₹3,219 Mil. Therefore, Marksans Pharma's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2025 was 4.27%.


Marksans Pharma Effective Interest Rate on Debt % Historical Data

The historical data trend for Marksans Pharma's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marksans Pharma Effective Interest Rate on Debt % Chart

Marksans Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.88 7.44 4.92 6.11 4.12

Marksans Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.93 4.79 5.31 5.38 4.27

Competitive Comparison of Marksans Pharma's Effective Interest Rate on Debt %

For the Drug Manufacturers - General subindustry, Marksans Pharma's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marksans Pharma's Effective Interest Rate on Debt % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Marksans Pharma's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Marksans Pharma's Effective Interest Rate on Debt % falls into.


;
;

Marksans Pharma Effective Interest Rate on Debt % Calculation

Marksans Pharma's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Mar. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Mar. 2024 )+Total Debt  (A: Mar. 2025 ))/ count )
=-1  *  -116.6/( (2440.61+3219.06)/ 2 )
=-1  *  -116.6/2829.835
=4.12 %

where

Total Debt  (A: Mar. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=1900.19 + 540.42
=2440.61

Total Debt  (A: Mar. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=2633.29 + 585.77
=3219.06

Marksans Pharma's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2024 )+Total Debt  (Q: Mar. 2025 ))/ count )
=-1  *  -137.4/( (0+3219.06)/ 1 )
=-1  *  -137.4/3219.06
=4.27 %

where

Total Debt  (Q: Mar. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=2633.29 + 585.77
=3219.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2025) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Marksans Pharma  (NSE:MARKSANS) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Marksans Pharma Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Marksans Pharma's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Marksans Pharma Business Description

Traded in Other Exchanges
Address
Veera Desai Extension Road, 11th Floor, Grandeur, Opposite Gundecha Symphony, Oshiwara, Andheri (West), Mumbai, MH, IND, 400053
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.

Marksans Pharma Headlines

No Headlines